The Role of Butirprost® in Combination With Antibiotics in Chronic Bacterial Prostatitis (CBP) Treatment

NCT06684626 PHASE3 COMPLETED

Bacterial prostatitis (BP) is a common prostatic infection characterized by pain and urinary symptoms, often with negative bacterial cultures from prostatic secretions. It affects young and older men bimodally and significantly impacts quality of life (QoL). Treatment typically involves antibiotics, but a multimodal approach with additional nutraceuticals may enhance outcomes. This work aims to assess the efficacy of Butirprost® in association with fluoroquinolones in patients with Chronic Bacterial Prostatitis (CBP).

Details

Lead sponsor	Federico II University
Phase	PHASE3
Status	COMPLETED
Enrolment	60
Start date	Fri Mar 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Sep 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Prostate Inflammation
• Prostate Disease
• Chronic Bacterial Prostatitis

Interventions

• Sodium Hyaluronate
• Levofloxacin 500mg

Countries

Italy